Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection.

ABSTRACT:

Background

The aim of this secondary analysis of the TESEO cohort is to identify, early in the course of treatment with tocilizumab, factors associated with the risk of progressing to mechanical ventilation and death and develop a risk score to estimate the risk of this outcome according to patients' profile.

Methods

Patients with COVID-19 severe pneumonia receiving standard of care + tocilizumab who were alive and free from mechanical ventilation at day 6 after treatment initiation were included in this retrospective, multicenter cohort study. Multivariable logistic regression models were built to identify predictors of mechanical ventilation or death by day-28 from treatment initiation and β-coefficients were used to develop a risk score. Secondary outcome was mortality. P

SUBMITTER: Mussini C 

PROVIDER: S-EPMC7901750 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature